Latin Resources Limited

LRS

Latin Resources Ltd. engages in the identification and definition of mineral resources in Latin America. The company is headquartered in Leederville, Western Australia. The company went IPO on 2010-09-21. The firm is focused on developing mineral projects in commodities with projects in South America and Australia. Its projects include Salinas Lithium project, Catamarca Lithium project, Cloud Nine Halloysite-Kaolin Deposit, CRC CARE Emissions Reduction Research project and MT-03 Copper project. The Salinas project is located approximately 10 km outside the town of Salinas. The project is located in the north-east of Minas Gerais, approximately 600 km north-east of Belo Horizonte. The Catamarca Lithium project has accumulated hard rock spodumene landholding in Argentina, totaling over 70,000 hectares. Cloud Nine Halloysite-Kaolin deposit is located approximately 300 kilometers (km) east of Perth in Western Australia and has demonstrated large scale resources of both halloysite and kaolin. The Company, through its subsidiary, Peruvian Latin Resources SAC (PLR), owns the MT03 project in southern Peru.

Nickel Industries Limited

NIC

Nickel Industries Ltd. is an exploration and development company, which focuses on nickel mining projects. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-08-20. The company is engaged in the production of nickel matte. The company holds interest in high pressure acid leach (HPAL) projects, producing mixed hydroxide precipitate (MHP) for use in the electric vehicle (EV) supply chain. Its segments include Nickel ore mining in Indonesia, Ranger Nickel rotary kiln electric furnace (RKEF) project in Indonesia and Singapore and the (HPAL) projects in Indonesia and Hong Kong. Its principal operations, located in Indonesia, are the Hengjaya Nickel, Oracle Nickel and RKEF projects located within the Indonesia Morowali Industrial Park (IMIP), the Angel Nickel RKEF Project within the Indonesia Weda Bay Industrial Park (IWIP) and the Hengjaya Mine, a large tonnage, high grade nickel laterite deposit in close proximity to the IMIP. The Hengjaya Nickel Project is a two-line Rotary Kiln Electric Furnace (RKEF) plant operating within the IMIP.

Arafura Rare Earths Ltd

ARU

Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is engaged in discovering, developing, and delivering pharmaceutical therapies. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).